Effectiveness of sulforaphane as a radiosensitizer for murine osteosarcoma cells

Sawai,Yasushi; Murata,Hiroaki; Horii,Motoyuki; Koto,Kazutaka; Matsui,Takaaki; Horie,Naoyuki; Tsuji,Yoshiro; Ashihara,Eishi; Maekawa,Taira; Kubo,Toshikazu; Fushiki,Shinji

doi:10.3892/or.2012.2195

Effectiveness of sulforaphane as a radiosensitizer for murine osteosarcoma cells

Authors:
- Yasushi Sawai
- Hiroaki Murata
- Motoyuki Horii
- Kazutaka Koto
- Takaaki Matsui
- Naoyuki Horie
- Yoshiro Tsuji
- Eishi Ashihara
- Taira Maekawa
- Toshikazu Kubo
- Shinji Fushiki
View Affiliations

Affiliations: Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan, Department of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan
Published online on: December 18, 2012 https://doi.org/10.3892/or.2012.2195
Pages: 941-945

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sulforaphane (SFN), a naturally occurring member of the isothiocyanate family, is effective against various types of malignant tumor cells. We studied whether the combination of SFN and radiation would be more effective against osteosarcoma cells when compared to these treatments alone. LM8 murine osteosarcoma cells were cultured with various concentrations of SFN for 24 h and/or 2 Gy X-irradiation. The effects of individual and combination treatments on the number of cells, the cell cycle, cell proliferation-related factors and apoptosis were analyzed. The combination of SFN plus radiation had significantly greater antitumor effects than either treatment alone. Exposure to SFN increased the population of cells in the G2/M phase. Combination treatment resulted in a higher percentage of cells being in sub-G1 than did SFN alone. In addition, the combination of SFN and radiation effectively induced nuclear fragmentation and apoptotic bodies, as shown by DAPI staining. The combination of SFN and 2 Gy radiation increased the cleavage and activation of caspase-3 compared with SFN or radiation alone, as shown by western blotting. Although radiation alone increased the phosphorylation of ERK and Akt proteins, the combination of SFN and radiation induced suppression of ERK and Akt phosphorylation when compared with radiation alone. We found that SFN enhanced the radiosensitivity of LM8 murine osteosarcoma cells by inducing apoptosis through G2/M-phase arrest and by inhibiting ERK and Akt activation. These findings suggest that SFN can be used as a radiosensitizer for osteosarcomas.

View Figures

View References

1	Unni KK and Inwards CY: Dahlin’s Bone Tumors, General Aspects and Data on 10,165 Cases. 6th edition. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 122–168. 2010
2	Ferrari S, Palmerini E, Staals EL, et al: The treatment of non-metastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future. Cancer Treat Res. 152:275–287. 2009. View Article : Google Scholar : PubMed/NCBI
3	Gelderblom H, Jinks RC, Sydes M, et al: Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 47:895–902. 2011. View Article : Google Scholar : PubMed/NCBI
4	Zalupski MM, Rankin C, Ryan JR, et al: Adjuvant therapy of osteosarcoma - A phase II trial: Southwest Oncology Group study 9139. Cancer. 100:818–825. 2004.PubMed/NCBI
5	Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K and Mankin HJ: Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am. 78:366–375. 1996.PubMed/NCBI
6	Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y and Ashihara T: Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res. 21:317–320. 2001.PubMed/NCBI
7	Sack H: Radiation therapy and chemotherapy of primary malignant tumors of the bone. Rontgenblatter. 29:424–429. 1976.(In German).
8	Schwarz R, Bruland O, Cassoni A, Schomberg P and Bielack S: The role of radiotherapy in osteosarcoma. Cancer Treat Res. 152:147–164. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ryu K, Murata H, Koto K, et al: Combined effects of bisphosphonate and radiation on osteosarcoma cells. Anticancer Res. 30:2713–2720. 2010.PubMed/NCBI
10	Quiet CA, Weichselbaum RR and Grdina DJ: Variation in radiation sensitivity during the cell cycle of two human squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 20:733–738. 1991. View Article : Google Scholar : PubMed/NCBI
11	Tell R, Heiden T, Granath F, Borg AL, Skog S and Lewensohn R: Comparison between radiation-induced cell cycle delay in lymphocytes and radiotherapy response in head and neck cancer. Br J Cancer. 77:643–649. 1998. View Article : Google Scholar : PubMed/NCBI
12	Yacoub A, Miller A, Caron RW, et al: Radiotherapy-induced signal transduction. Endocr Relat Cancer. 13:S99–S114. 2006. View Article : Google Scholar : PubMed/NCBI
13	Marampon F, Gravina GL, Di Rocco A, et al: MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther. 10:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
14	Matsui TA, Sowa Y, Yoshida T, et al: Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis. 27:1768–1777. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Talalay P, Cho CG and Posner GH: A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA. 89:2399–2403. 1992. View Article : Google Scholar : PubMed/NCBI
16	Jackson SJT and Singletary KW: Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis. 25:219–227. 2004. View Article : Google Scholar : PubMed/NCBI
17	Gamet-Payrastre L, Li P, Lumeau S, et al: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60:1426–1433. 2000.PubMed/NCBI
18	Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G and Hrelia P: Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis. 23:581–586. 2002. View Article : Google Scholar : PubMed/NCBI
19	Parnaud G, Li P, Cassar G, et al: Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr Cancer. 48:198–206. 2004. View Article : Google Scholar : PubMed/NCBI
20	Singh SV, Herman-Antosiewicz A, Singh AV, et al: Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem. 279:25813–25822. 2004. View Article : Google Scholar : PubMed/NCBI
21	Matsui TA, Murata H, Sakabe T, et al: Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo. Oncol Rep. 18:1263–1268. 2007.PubMed/NCBI
22	Roy SK, Srivastava RK and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
23	Shankar S, Ganapathy S and Srivastava RK: Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 14:6855–6866. 2008. View Article : Google Scholar
24	Yu D, Sekine-Suzuki E, Xue L, Fujimori A, Kubota N and Okayasu R: Chemopreventive agent sulforaphane enhances radiosensitivity in human tumor cells. Int J Cancer. 125:1205–1211. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kotowski U, Heiduschka G, Brunner M, et al: Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane. Strahlenther Onkol. 187:575–580. 2011. View Article : Google Scholar : PubMed/NCBI
26	Asai T, Ueda T, Itoh K, et al: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 76:418–422. 1998. View Article : Google Scholar : PubMed/NCBI
27	Kim MR, Zhou L, Park BH and Kim JR: Induction of G₂/M arrest and apoptosis by sulforaphane in human osteosarcoma U2-OS cells. Mol Med Rep. 4:929–934. 2011.PubMed/NCBI
28	Hu R, Hebbar V, Kim BR, et al: In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther. 310:263–271. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA and Talalay P: Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta. 316:43–53. 2002. View Article : Google Scholar
30	Sheplan LJ and Juliano JJ: Use of radiation therapy for patients with soft-tissue and bone sarcomas. Cleve Clin J Med. 77:S27–S29. 2010. View Article : Google Scholar : PubMed/NCBI
31	Zhao Y, Jiang W, Li B, et al: Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int Immunopharmacol. 11:2039–2046. 2011. View Article : Google Scholar : PubMed/NCBI
32	Yu J, Liu F, Sun M, Sun Z and Sun S: Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinoma cells by tetrandrine. Cancer Biother Radiopharm. 26:437–442. 2011. View Article : Google Scholar : PubMed/NCBI
33	Forde JC, Maginn EN, McNamara G, et al: Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro. Cancer Biol Ther. 11:421–428. 2011. View Article : Google Scholar : PubMed/NCBI
34	PosthumaDeBoer J, Würdinger T, Graat HCA, et al: WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 11:1562011. View Article : Google Scholar : PubMed/NCBI
35	Kim IA, Bae SS, Fernandes A, et al: Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 65:7902–7910. 2005.PubMed/NCBI